Species | Target name | Source | Bibliographic reference |
---|---|---|---|
Homo sapiens | lamin A/C | Starlite/ChEMBL | No references |
Mus musculus | RAR-related orphan receptor gamma | Starlite/ChEMBL | No references |
Homo sapiens | TAR DNA binding protein | Starlite/ChEMBL | No references |
Equus caballus | Ferritin light chain | Starlite/ChEMBL | No references |
Species | Potential target | Known druggable target | Length | Alignment span | Identity |
---|---|---|---|---|---|
Schistosoma mansoni | apoferritin-2 | Ferritin light chain | 175 aa | 142 aa | 29.6 % |
Schistosoma japonicum | Ferritin, putative | Ferritin light chain | 175 aa | 144 aa | 24.3 % |
Echinococcus granulosus | expressed protein | Ferritin light chain | 175 aa | 146 aa | 28.8 % |
Echinococcus multilocularis | expressed protein | Ferritin light chain | 175 aa | 146 aa | 30.1 % |
Schistosoma mansoni | ferritin | Ferritin light chain | 175 aa | 171 aa | 44.4 % |
Schistosoma mansoni | ferritin | Ferritin light chain | 175 aa | 171 aa | 43.9 % |
Schistosoma mansoni | apoferritin-2 | Ferritin light chain | 175 aa | 146 aa | 28.8 % |
Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Loa Loa (eye worm) | hypothetical protein | 0.0154 | 0.5478 | 0.5478 |
Brugia malayi | Intermediate filament tail domain containing protein | 0.0033 | 0.0688 | 0.0602 |
Loa Loa (eye worm) | TAR-binding protein | 0.0076 | 0.2422 | 0.2422 |
Trichomonas vaginalis | conserved hypothetical protein | 0.0115 | 0.3925 | 0.5 |
Loa Loa (eye worm) | hypothetical protein | 0.0154 | 0.5478 | 0.5478 |
Echinococcus multilocularis | lamin | 0.0033 | 0.0688 | 0.2772 |
Loa Loa (eye worm) | hypothetical protein | 0.0115 | 0.3925 | 0.3925 |
Echinococcus granulosus | intermediate filament protein | 0.0033 | 0.0688 | 0.2772 |
Loa Loa (eye worm) | RNA recognition domain-containing protein domain-containing protein | 0.0076 | 0.2422 | 0.2422 |
Loa Loa (eye worm) | hypothetical protein | 0.0115 | 0.3925 | 0.3925 |
Schistosoma mansoni | tar DNA-binding protein | 0.0076 | 0.2422 | 1 |
Loa Loa (eye worm) | cytoplasmic intermediate filament protein | 0.0017 | 0.0092 | 0.0092 |
Brugia malayi | hypothetical protein | 0.0115 | 0.3925 | 0.3869 |
Brugia malayi | hypothetical protein | 0.0154 | 0.5478 | 0.5436 |
Loa Loa (eye worm) | hypothetical protein | 0.0033 | 0.0688 | 0.0688 |
Loa Loa (eye worm) | hypothetical protein | 0.0032 | 0.0665 | 0.0665 |
Loa Loa (eye worm) | hypothetical protein | 0.0115 | 0.3925 | 0.3925 |
Echinococcus multilocularis | lamin dm0 | 0.0033 | 0.0688 | 0.2772 |
Loa Loa (eye worm) | RNA binding protein | 0.0076 | 0.2422 | 0.2422 |
Echinococcus granulosus | lamin dm0 | 0.0033 | 0.0688 | 0.2772 |
Onchocerca volvulus | 0.0115 | 0.3925 | 0.3476 | |
Brugia malayi | LBP / BPI / CETP family, C-terminal domain containing protein | 0.0154 | 0.5478 | 0.5436 |
Loa Loa (eye worm) | hypothetical protein | 0.0154 | 0.5478 | 0.5478 |
Onchocerca volvulus | 0.0154 | 0.5478 | 0.5144 | |
Loa Loa (eye worm) | LBP/BPI/CETP family domain-containing protein | 0.0154 | 0.5478 | 0.5478 |
Echinococcus multilocularis | tar DNA binding protein | 0.0076 | 0.2422 | 1 |
Schistosoma mansoni | tar DNA-binding protein | 0.0076 | 0.2422 | 1 |
Brugia malayi | RNA recognition motif domain containing protein | 0.0076 | 0.2422 | 0.2351 |
Schistosoma mansoni | tar DNA-binding protein | 0.0076 | 0.2422 | 1 |
Loa Loa (eye worm) | hypothetical protein | 0.0016 | 0.0024 | 0.0024 |
Loa Loa (eye worm) | LBP/BPI/CETP family domain-containing protein | 0.0154 | 0.5478 | 0.5478 |
Echinococcus granulosus | lamin | 0.0033 | 0.0688 | 0.2772 |
Echinococcus multilocularis | musashi | 0.0033 | 0.0688 | 0.2772 |
Echinococcus granulosus | tar DNA binding protein | 0.0076 | 0.2422 | 1 |
Loa Loa (eye worm) | intermediate filament protein | 0.0033 | 0.0688 | 0.0688 |
Brugia malayi | TAR-binding protein | 0.0076 | 0.2422 | 0.2351 |
Brugia malayi | hypothetical protein | 0.0154 | 0.5478 | 0.5436 |
Brugia malayi | RNA binding protein | 0.0076 | 0.2422 | 0.2351 |
Loa Loa (eye worm) | hypothetical protein | 0.0154 | 0.5478 | 0.5478 |
Brugia malayi | intermediate filament protein | 0.0033 | 0.0688 | 0.0602 |
Brugia malayi | LBP / BPI / CETP family, C-terminal domain containing protein | 0.0154 | 0.5478 | 0.5436 |
Brugia malayi | LBP/BPI | 0.0115 | 0.3925 | 0.3869 |
Onchocerca volvulus | 0.0154 | 0.5478 | 0.5144 | |
Schistosoma mansoni | tar DNA-binding protein | 0.0076 | 0.2422 | 1 |
Loa Loa (eye worm) | hypothetical protein | 0.0154 | 0.5478 | 0.5478 |
Brugia malayi | LBP / BPI / CETP family, C-terminal domain containing protein | 0.0154 | 0.5478 | 0.5436 |
Loa Loa (eye worm) | hypothetical protein | 0.0115 | 0.3925 | 0.3925 |
Schistosoma mansoni | tar DNA-binding protein | 0.0076 | 0.2422 | 1 |
Loa Loa (eye worm) | intermediate filament tail domain-containing protein | 0.0033 | 0.0688 | 0.0688 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
IC50 (functional) | > 100 uM | PubChem BioAssay. Dose Response Confirmation of SKN-1 Inhibitor hits in a fluorescence ratio assay. (Class of assay: confirmatory) | ChEMBL. | No reference |
Potency (functional) | = 1 um | PUBCHEM_BIOASSAY: qHTS for inhibitors of ROR gamma transcriptional activity. (Class of assay: confirmatory) | ChEMBL. | No reference |
Potency (binding) | = 6.3096 um | PUBCHEM_BIOASSAY: qHTS Assay for Identification of Novel General Anesthetics. In this assay, a GABAergic mimetic model system, apoferritin and a profluorescent 1-aminoanthracene ligand (1-AMA), was used to construct a competitive binding assay for identification of novel general anesthetics (Class of assay: confirmatory) [Related pubchem assays: 2385 (Probe Development Summary for Identification of Novel General Anesthetics), 2323 (Validation apoferritin assay run on SigmaAldrich LOPAC1280 collection)] | ChEMBL. | No reference |
Potency (functional) | 7.0795 uM | PubChem BioAssay. qHTS of TDP-43 Inhibitors. (Class of assay: confirmatory) | ChEMBL. | No reference |
Potency (functional) | = 15.8489 um | PUBCHEM_BIOASSAY: qHTS Assay for Modulators of Lamin A Splicing. (Class of assay: confirmatory) | ChEMBL. | No reference |
Potency (functional) | = 35.4813 um | PUBCHEM_BIOASSAY: qHTS Multiplex Assay to Identify Dual Action Probes in a Cell Model of Huntington: Aggregate Formation (GFP). (Class of assay: confirmatory) [Related pubchem assays: 1482, 1471 ] | ChEMBL. | No reference |
Potency (functional) | = 35.4813 um | PUBCHEM_BIOASSAY: qHTS Assay for Enhancers of SMN2 Splice Variant Expression. (Class of assay: confirmatory) | ChEMBL. | No reference |
Potency (functional) | = 35.4813 um | PUBCHEM_BIOASSAY: VP16 counterscreen qHTS for inhibitors of ROR gamma transcriptional activity. (Class of assay: confirmatory) | ChEMBL. | No reference |
Potency (functional) | = 39.8107 um | PUBCHEM_BIOASSAY: qHTS Assay for Promiscuous and Specific Inhibitors of Cruzain (without detergent). (Class of assay: confirmatory) [Related pubchem assays: 2158 (Confirmation qHTS Assay for Inhibitors of Cruzain), 2249 (Probe Development Summary of Promiscuous Inhibitors (Artifacts) of Cruzain), 2161 (qHTS Assay for Inhibitors of Papain: Counterscreen for Cruzain Assay), 1478 (qHTS Assay for Promiscuous and Specific Inhibitors of Cruzain (with detergent))] | ChEMBL. | No reference |
Potency (functional) | = 39.8107 um | PUBCHEM_BIOASSAY: qHTS Assay for Inhibitors of Aldehyde Dehydrogenase 1 (ALDH1A1). (Class of assay: confirmatory) [Related pubchem assays: 1030 (qHTS Validation Assay for Inhibitors of aldehyde dehydrogenase 1 (ALDH1A1))] | ChEMBL. | No reference |
Potency (functional) | 67.4555 uM | PubChem BioAssay. qHTS Assay to Find Inhibitors of Pin1. (Class of assay: confirmatory) | ChEMBL. | No reference |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.